Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation - Wikidata - wikimedia - TriplyDB

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

http://www.wikidata.org/entity/Q35230678

about

The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives Review of the Structural and Dynamic Mechanisms of PPARγ Partial Agonism Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes The inflammatory response in sepsis Nuclear receptors in bone physiology and diseases Something old, something new and something very old: drugs for treating type 2 diabetes Targeting xenobiotic receptors PXR and CAR for metabolic diseases Modulation of the transcriptional activity of peroxisome proliferator-activated receptor gamma by protein-protein interactions and post-translational modifications PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass Multidomain integration in the structure of the HNF-4α nuclear receptor complex GQ-16, a Novel Peroxisome Proliferator-activated Receptor (PPAR ) Ligand, Promotes Insulin Sensitization without Weight Gain Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network A natural-product switch for a dynamic protein interface Identification of PPARgamma partial agonists of natural origin (II): in silico prediction in natural extracts with known antidiabetic activity CHARMM Force Field Parameterization of Peroxisome Proliferator-Activated Receptor γ Ligands Protein Footprinting Comes of Age: Mass Spectrometry for Biophysical Structure Assessment.Integrating mass spectrometry of intact protein complexes into structural proteomics Peptide-column interactions and their influence on back exchange rates in hydrogen/deuterium exchange-MS.MicroRNA-27a promotes podocyte injury via PPARγ-mediated β-catenin activation in diabetic nephropathy.A photocleavable masked nuclear-receptor ligand enables temporal control of C. elegans development.Leptin revisited: its mechanism of action and potential for treating diabetes.Artemisia scoparia enhances adipocyte development and endocrine function in vitro and enhances insulin action in vivo Repression of phosphoinositide-dependent protein kinase 1 expression by ciglitazone via Egr-1 represents a new approach for inhibition of lung cancer cell growth Role of the adipose PPARγ-adiponectin axis in susceptibility to stress and depression/anxiety-related behaviors.Adipose tissue NAD+ biology in obesity and insulin resistance: From mechanism to therapy Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets.Diosgenin relieves goiter via the inhibition of thyrocyte proliferation in a mouse model of Graves' disease.Betulinic acid is a PPARγ antagonist that improves glucose uptake, promotes osteogenesis and inhibits adipogenesis.Role of the SIK2-p35-PJA2 complex in pancreatic β-cell functional compensation.CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models.High-fat and obesogenic diets: current and future strategies to fight obesity and diabetes.A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity The peroxisome-proliferator activated receptor-γ agonist pioglitazone modulates aberrant T cell responses in systemic lupus erythematosus.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.The serine/threonine phosphatase PPM1B (PP2Cβ) selectively modulates PPARγ activity.Noncanonical mechanisms to regulate nuclear receptor signaling.Retinaldehyde dehydrogenase 1 deficiency inhibits PPARγ-mediated bone loss and marrow adiposity.

P2860

Q24601222-A2E9F83F-E710-45F5-9125-FB2765F98E96 Q26747009-2B44D9BB-7FF5-4277-9ECF-5BE0FEABBBD0 Q26782232-3CD264E4-EC54-4D0F-A2A3-6C12EB81CC08 Q26829985-884C7BCD-170E-459F-8C50-57EA400AEDD8 Q26849300-2DB5CB5A-3B16-491B-A772-C0001096F872 Q26853017-E678D811-687A-4174-B51D-DF4C7865BC2F Q26865663-A93153BE-630D-40EE-8859-7AF2FD7398C9 Q27011149-AEAF0804-5858-449C-A32D-6CC2813C3117 Q27015807-6C006F6B-68DD-4F4E-9F6C-10BF4CF00B3B Q27024799-553B4DE1-FE93-4A78-B69A-A518CAFF02BD Q27334866-35EA4B00-6197-4C96-9E30-2F23D2A0B868 Q27676792-7A711A2E-7E3F-46F8-92ED-DF2A26BEBA20 Q27679090-6AE80ED4-CFB2-4B42-99F7-0697C9FCD771 Q27679376-B4D6307E-8036-4805-9CEE-7BCA05B49062 Q27683572-8BE26474-08DC-48D0-998A-B5FD7753D552 Q27690221-F718C62D-688E-4D6A-8E1D-39F56B5CE680 Q28486003-C1454C08-38EF-44BA-BCDA-BD261534C92F Q28817182-CF1E97C5-7C3B-4879-810E-3479FC0522C0 Q30399662-0B6DE396-7B63-4F65-BF1D-378EE815638C Q30417001-B9703639-FE1B-4DFD-85E3-B4B4B9275BDE Q30430210-2F8A5A3F-2F98-405E-8902-2FF276628836 Q30844796-D8D61661-AAC2-4416-A7A2-54B6389857B2 Q33590721-DDEAF08E-5956-433D-A86C-542FE35C5588 Q33602487-7E7D4B1D-DE40-4960-8ADA-9952534540FD Q33733950-1BFF09ED-B181-494A-B95A-39C361B42DEC Q33770896-9F1B9A5F-BAF4-449E-8201-6B28BDF30535 Q33790412-6DB7E1E6-F986-4EA4-B111-7786D1EAC5E6 Q33791807-BD55B915-154A-47ED-9799-987933F55AAD Q33808884-F5D700C2-1484-4636-9898-68B55093BBAB Q33823673-BF5861FA-8597-42C8-8A39-EF816402ABBD Q33916179-73C14F63-29EC-46DE-B78A-8CD64AFB4017 Q33936173-60036380-F4E2-4BDF-BA1C-875F791A6CC6 Q34067485-A650A63E-1D37-43D0-8598-6E043D446847 Q34212924-5A7FA389-7D4C-4219-9654-D6D0D8049794 Q34249161-1C3D17E9-3CEE-4A58-8E88-79249AAC38D1 Q34284885-D9862524-4A1B-40E0-8FEE-DB0CB224A666 Q34315432-CAAFB8D8-2B9F-4DEB-8E8E-013568B7D447 Q34322660-2E224C1A-7DB9-4645-BF2E-883F2EDD6B1C Q34338685-62F72A1C-FA4B-4407-86D9-0EFB88AACFCA Q34402668-BC19019F-9BDD-4D75-949A-1DBC5682D945

P2860

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

http://www.wikidata.org/entity/Q35230678

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

@ast

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

@en

type

label

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

@ast

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

@en

prefLabel

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

@ast

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

@en

P1433

Q35230678-05D0ADF0-6F8B-4AFE-AEC9-31BE7CCB25B8

P1476

Q35230678-EFBFA696-3731-4E38-8754-C8A7510CB2D9

P2093

Q35230678-1F6CCFD6-9156-4ABD-BA4F-E26F70F31376

Q35230678-32529F5D-B8C5-4D7D-A9E0-DFF8A4B222F2

Q35230678-4D64F1FA-FF23-4AF0-9114-4F50A7C4CA7A

Q35230678-64B24C05-6D3B-4E1F-8F86-0B31FE28B58F

Q35230678-78665599-2BBC-441B-84DB-C33D90410DB6

Q35230678-7A34F650-F050-459A-916A-A553E0967820

Q35230678-819D96DD-96FA-4D07-915D-A1DCB53C6D34

Q35230678-9EAA184B-6D29-4F5B-B9AB-2340D4D7DF69

Q35230678-9FECCB2B-88D9-4E26-B4D4-1F90920FC5D3

Q35230678-A5E7013D-8B96-4CF3-8013-348432FFB57D

P2860

Q35230678-06AA412F-CBDE-43BA-B4DB-9406AC0DACD5

Q35230678-075AC05A-1FA5-48B6-803A-2A3677DBE90B

Q35230678-0F650801-7532-4219-BCD1-529B9F8382E9

Q35230678-20C9D108-00E3-4F84-A98B-E00C77F3D396

Q35230678-2225C872-001C-4A0A-A0C4-8C1523585480

Q35230678-3C137AD9-0353-43CE-AD68-31AEC4DE3ED9

Q35230678-412C7ACE-98BF-4ADC-BCD0-1DE8E937D7E0

Q35230678-4575DFF4-3028-4FBB-9CB5-0695708AAB7F

Q35230678-46BEC7A3-0C11-4E2F-AE3A-6AF8BE6434A8

Q35230678-4A2193DB-B7DC-4CE0-902C-069DA9D76250

P2888

Q35230678-0BBF99C9-E9F4-4E57-9122-E9038A11820A

P304

Q35230678-4D907A61-8762-4927-94DE-5036823DB4C3

P31

Q35230678-30E7C015-205F-400A-9224-17F5A970B879

P356

Q35230678-62854148-6139-4A4F-BE1E-5498523A073C

P407

Q35230678-F7D36167-B168-4CBA-B5CA-257AF5498D6C

P433

Q35230678-AADC7457-BB07-4822-9844-5B972FE6C49B

P478

Q35230678-2C98D4BB-78E6-4CE6-9A6C-71EF8B1CC907

P50

Q35230678-23EE3B71-1BF0-4048-91BC-D14485434274

Q35230678-3186F1F6-0E8B-431D-8A2F-13FBDE26BE4B

Q35230678-6ED47ED8-E5A6-44EC-B62C-D76E35246C4F

P577

Q35230678-AA35D958-EF04-48E8-B10A-82747A3C5793

P5875

Q35230678-C6C2F68E-C807-42C9-A118-615AFE4C0474

P6179

Q35230678-91DF9772-4CD6-4BA2-B9E7-31F94825BE79

P698

Q35230678-D4B0848D-7D8D-4831-BA7F-6A4F66F7142F

P921

Q35230678-C64F0A4A-F8F4-4F13-A5D1-19FB64DD6148

P932

Q35230678-F51B6B8C-CB2D-40BC-833F-9339B719FE61

P356

P1433

P1476

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

@en

P2093

Bruce M Spiegelman

http://www.w3.org/2001/XMLSchema#string

Dana S Kuruvilla

http://www.w3.org/2001/XMLSchema#string

David P Marciano

http://www.w3.org/2001/XMLSchema#string

Dina Laznik

http://www.w3.org/2001/XMLSchema#string

Dušica Vidović

http://www.w3.org/2001/XMLSchema#string

Jang Hyun Choi

http://www.w3.org/2001/XMLSchema#string

John B Bruning

http://www.w3.org/2001/XMLSchema#string

Michael D Cameron

http://www.w3.org/2001/XMLSchema#string

Michael J Chalmers

http://www.w3.org/2001/XMLSchema#string

Naresh Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro

Partial agonists activate PPARgamma using a helix 12 independent mechanism

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma

Severely impaired adipsin expression in genetic and acquired obesity

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

Nonhypoglycemic effects of thiazolidinediones.

Glucose clamp technique: a method for quantifying insulin secretion and resistance.

P2888

P304

477-481

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE10383

http://www.w3.org/2001/XMLSchema#string

P407

P433

7365

http://www.w3.org/2001/XMLSchema#string

P478

477

http://www.w3.org/2001/XMLSchema#string

P50

Michael J. Jurczak

Alexander S Banks

Gerald I. Shulman

P577

2011-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51618576

http://www.w3.org/2001/XMLSchema#string

P6179

1004606531

http://www.w3.org/2001/XMLSchema#string

P698

21892191

http://www.w3.org/2001/XMLSchema#string

P921

phosphorylation

P932

3179551

http://www.w3.org/2001/XMLSchema#string